Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Haimovici R, D’Amico D, Gragoudas ES, Sokol S . The expanded clinical spectrum of deferrioxamine. Ophthalmology 2002; 109: 164–171.
Lakhanpal V, Schocket SS, Jiji R . Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 1984; 91: 443–451.
Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N et al. Visual and auditory neurotoxicity in patients receiving subcutaneous desferoxamine infusions. N Eng J Med 1986; 314: 869–873.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
The corresponding author has the right to grant on behalf of all authors, and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its licensees to permit this article (if accepted) to be published in British Journal of Ophthalmology and any other BMJPGL products to exploit all subsidiary rights, as set out in our licence (http://group.bmj.com/products/journals/instructions-for-authors/licence-forms).
Rights and permissions
About this article
Cite this article
Ng, W., Chandra, P. Optical coherence tomography in desferrioxamine ocular toxicity: a place in screening and monitoring?. Eye 25, 959–961 (2011). https://doi.org/10.1038/eye.2011.57
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2011.57
